Shares of Relief Therapeutics Holding SA (OTCMKTS:RLFTF – Get Free Report) traded up 0.6% on Thursday . The company traded as high as $1.82 and last traded at $1.82. 1,511 shares were traded during mid-day trading, a decline of 6% from the average session volume of 1,601 shares. The stock had previously closed at $1.81.
Relief Therapeutics Stock Down 2.2%
The company has a fifty day moving average of $2.96 and a two-hundred day moving average of $3.25.
Relief Therapeutics Company Profile
Relief Therapeutics AG is a clinical‐stage biopharmaceutical company focused on the development of novel therapies for rare and critical care indications. Headquartered in Geneva, Switzerland, the company leverages its expertise in peptide biology to address diseases with high unmet need, including acute respiratory distress syndrome (ARDS) and other serious pulmonary and inflammatory conditions.
The company’s lead product candidate, RLF‐100 (aviptadil), is a synthetic formulation of vasoactive intestinal peptide (VIP) being evaluated for the treatment of ARDS and COVID-19–associated respiratory failure.
See Also
- Five stocks we like better than Relief Therapeutics
- Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!
- How a Family Trust May Be Able To Help Preserve Your Wealth
- A U.S. “birthright” claim worth trillions – activated quietly
- “Fed Proof” Your Bank Account with THESE 4 Simple Steps
- NEW LAW: Congress Approves Setup For Digital Dollar?
Receive News & Ratings for Relief Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relief Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
